Diarrhoea News and Research

RSS

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Biótica researchers develop automated laboratory system that rapidly detects E. coli bacterium

A Castellón-based biotechnology R&D project by Biótica has been successfully certified by the Centre for Technological and Industrial Development (CDTI, in Spanish), of the Spanish Ministry of Economy and Competitiveness.

20 May 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).

19 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Depression is the leading cause of illness in adolescents, shows WHO's report

WHO's "Health for the world's adolescents" report reveals that depression is the predominant cause of illness and disability for both boys and girls aged 10 to 19 years.

15 May 2014

Zinc supplements reduce diarrhoea and infections in malnourished children

Zinc supplements reduce diarrhoea and other infections in malnourished children, and may prevent death, according to a new study published in The Cochrane Library.

15 May 2014

Triple therapy shows promise for severe PAH

Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

New Ebola variant identified in Guinea

Performed in less than a month, sequencing of the complete genome and subsequent phylogenetic analysis show that the virus present in Guinea forms a clade (variant) that is distinct from strains previously identified in the Democratic Republic of Congo and in Gabon. Epidemiological investigations also linked the laboratory confirmed cases with the initial deaths recorded during the December 2013 outbreak.

25 Apr 2014

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib.

14 Apr 2014

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial.

11 Apr 2014

Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people living in residential care facilities are at increased risk of severe illness or death from outbreaks of viral gastroenteritis.

3 Apr 2014

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Healthy children attending day-care centres have a significantly lower risk of getting diarrhoea or respiratory tract infections when given a daily supplement of Lactobacillus reuteri Protectis, a study in 336 children shows. "Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes.

17 Mar 2014

Study shows SuperMum campaign improves handwashing behaviour

An analysis of a unique “SuperMum” handwashing campaign shows for the first time that using emotional motivators, such as feelings of disgust and nurture, rather than health messages, can result in significant, long-lasting improvements in people’s handwashing behaviour, and could in turn help to reduce the risk of infectious diseases.

4 Mar 2014

Altering sunitinib dosing schedule improves tolerability

Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.

21 Feb 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1